Madhav Prasad Yadav Selected Research

Therapeutics

3/2024	[177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study.
1/2024	Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
7/2022	Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant 225Ac-DOTATATE Targeted Alpha Therapy and Capecitabine: A Real-world Scenario Management Based Long-term Outcome Study.
6/2022	First-in-Human Experience With 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an Uncommon Case of Aggressive Medullary Thyroid Carcinoma Clinically Mimicking as Anaplastic Thyroid Cancer.
1/2022	Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study.
1/2022	Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study.
1/2021	Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
1/2021	A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy.
1/2020	Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
1/2020	Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Madhav Prasad Yadav Research Topics

Disease

9	Prostatic Neoplasms (Prostate Cancer) 03/2024 - 08/2016
8	Neoplasm Metastasis (Metastasis) 12/2023 - 08/2016
7	Neoplasms (Cancer) 03/2023 - 01/2020
4	Neuroendocrine Tumors (Neuroendocrine Tumor) 07/2022 - 10/2018
3	Thyroid Neoplasms (Thyroid Cancer) 01/2023 - 01/2022
2	medullary Thyroid cancer 01/2023 - 06/2022
2	Brain Neoplasms (Brain Tumor) 01/2023 - 01/2021
2	Paraganglioma (Paragangliomas) 01/2022 - 02/2019
2	Pain (Aches) 01/2022 - 10/2020
2	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2017
1	Gastro-enteropancreatic neuroendocrine tumor 07/2022
1	Anaplastic Thyroid Carcinoma 06/2022
1	Glioblastoma (Glioblastoma Multiforme) 12/2020
1	Disease Progression 01/2020
1	Carcinoid Heart Disease 10/2018
1	Parathyroid Neoplasms (Parathyroid Neoplasm) 06/2018
1	Adenoma (Adenomas) 06/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 04/2014
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 04/2014

Drug/Important Bio-Agent (IBA)

8	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2023 - 04/2014
4	Radioisotopes (Radionuclides)IBA 03/2023 - 10/2018
3	177Lu-PSMA-617IBA 12/2023 - 01/2020
3	RadiopharmaceuticalsIBA 03/2023 - 10/2020
3	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2021
2	AntigensIBA 01/2024 - 01/2019
2	gallium 68 PSMA-11IBA 12/2023 - 01/2020
2	Capecitabine (Xeloda)FDA Link 07/2022 - 02/2019
2	Somatostatin Receptors (Somatostatin Receptor)IBA 07/2022 - 06/2018
2	Analgesics (Analgesic Drugs)IBA 01/2022 - 10/2020
2	68Ga-DOTANOCIBA 07/2019 - 06/2018
2	lutetium Lu 177 dotatateIBA 02/2019 - 06/2018
1	Actinium-225IBA 01/2024
1	Hormones (Hormone)IBA 12/2023
1	Chromogranin AIBA 06/2022
1	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 06/2022
1	Tyrosine Kinase InhibitorsIBA 01/2022
1	Chelating AgentsIBA 11/2021
1	Lutetium-177IBA 11/2021
1	Prostate-Specific Antigen (Semenogelase)IBA 01/2020
1	Peptide Receptors (Peptide Receptor)IBA 02/2019
1	fluorocholineIBA 06/2018
1	Sodium Fluoride (Ossin)FDA Link 01/2017
1	AcidsIBA 01/2017
1	177Lu-DKFZ-PSMA-617IBA 01/2017
1	lutetium ethylenediaminetetramethylene phosphonic acidIBA 08/2016
1	CD20 AntigensIBA 04/2014
1	Rituximab (Mabthera)FDA Link 04/2014
1	Monoclonal AntibodiesIBA 04/2014
1	Immunoconjugates (Immunoconjugate)IBA 04/2014

Therapy/Procedure

16	Therapeutics 03/2024 - 08/2016
9	Castration 03/2024 - 08/2016
6	Precision Medicine 01/2023 - 01/2017
1	Salvage Therapy 01/2022
1	Parathyroidectomy 06/2018
1	Radioimmunotherapy 04/2014